[The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy].  Long-term disease modifying therapy (DMD) therapy is the basis of modern MS treatment, effiecacy of which is modulated by the patient's adherence to therapy.
One of the possible solutions of low adherence improvement is the use of innovative drugs and the development of more convenient regimens of injectable medications.  This article gives a brief review of peg-interferon Î²-1a clinical trials.
